Timing of Initiating Glycopeptide Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: The Impact on Clinical Outcome
Table 1
Factors affecting when GP therapy was initiated in patients with MRSA bacteremia.
Variable
GP therapy was initiated and stratified according to the timing of preliminary BC indicating SLO growth, No. (%)
-value
Before and within 24 h
After 24 h
No. of patients
191 (56.2)
148 (43.8)
Age in years, median (range)
62 (28–98)
63 (25–88)
0.89
Male gender
111 (58.1)
103 (69.6)
0.03
Underlying disease or condition
Cardiovascular disease
26 (13.6)
23 (15.5)
0.64
Diabetes mellitus
76 (39.8)
61 (41.2)
0.82
Uremia requiring dialysis
30 (15.7)
36 (24.3)
0.05
Decompensated liver cirrhosis
32 (16.8)
15 (10.1)
0.08
Malignancies
32 (16.8)
32 (21.6)
0.26
Prosthetic device implantation
21 (10.9)
20 (13.5)
0.51
Severity-of-illness markera
Nosocomial acquisition
141 (73.8)
104 (70.3)
0.54
Intensive care unit admission
51 (26.7)
24 (16.2)
0.03
APACHE II score, median (range)
20 (7–30)
17 (2–24)
0.07
APACHE II score > 15
34 (17.8)
10 (6.8)
<0.01
Source of infectionb
Catheter-related infection
18 (9.4)
22 (14.9)
0.13
Endovascular infection
3 (1.6)
6 (4.1)
0.19
Soft-tissue infection
55 (28.8)
43 (29.1)
1.00
Osteomyelitis
44 (23.6)
23 (15.5)
0.10
Urinary tract infection
1 (0.5)
3 (2.0)
0.32
Pneumonia
35 (18.3)
16 (10.8)
0.07
Primary bacteremia
46 (24.1)
28 (18.9)
0.29
BC: blood culture; GP: glycopeptide; MRSA: methicillin-resistant S. aureus; No.: number.
aAt time of blood culture sampling.
bSome patients had more than one infected site.
